Technology

Market Opportunity – Cell Therapy Research

PatrickDriscoll
2 Min Read
Neurological disorders or injuries are those affecting the central nervous system (brain and spinal cord) or peripheral nervous system (PNS). Neurodegenerative diseases primarily involve neural deterioration. Causes can include: traumatic brain, spinal cord or nerve injury, genetic disorders, congenital abnormality or disorders, infections, and lifestyle or environmental health problems (including malnutrition).
Structural, biochemical or electrical abnormalities in the brain or spinal cord, or in the nerves leading to or from them, can result in symptoms such as paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion, pain and altered levels of consciousness. Disorders in neurology that represent targets of cell therapy research include stroke, Parkinson’s Disease, Alzheimer’s Disease, epilepsy, traumatic brain injury, central nervous system and spinal cord diseases — amyotropic lateral sclerosis (Lou Gehrig’s Diseas), multiple sclerosis, neuromuscular/muscular dystrophy). Considering only the numbers of Americans, there is a large population of potential patients:
  • Stroke: 700,000 per year
  • Parkinson’s: 4.5 million prevalence
  • Alzheimer’s: 1 million prevalence
  • Epilepsy: 200,00 per year
  • Traumatic brain injury: 1.4 million prevalence
  • Central nervous system and spinal cord disease: 1 million prevalence

Companies with active product development for cell therapy in neurological applications include: Aastrom Bioscience Inc., Aeolus Pharmaceuticals, Aldagen, Inc., Athersys, Inc., BeFutur Biotechnologies, BrainStorm Cell Therapeutics, Inc., co.don AG, ES Cell International, Geron Corporation, Innogenetics, Integra LifeSciences Inc., Living Cell Technologies Ltd., Medtronic, Neuralstem, Inc., NeuroGeneration, Inc., NeuroNova AB, Osteotech, Pluristem Therapeutics, Inc., Polyganics BV, ProNeuron Biotechnologies, Inc., ReInnervate Ltd., ReNeuron Ltd., Sernova Corp., Stem Cell Pharma Inc., StemCells Inc., Targeted Genetics Corporation, TEI Biosciences Inc., Transition Therapeutics Inc, and TriStem Corporation. Data on cell and tissue engineering therapy markets and products under development is provided in MedMarket Diligence Report #S520, “Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018.”

TAGGED:
Share This Article
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version